Endocrine manifestations of diphenylhydantoin therapy.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000311:Adrenal Glands / Q000187:drug effects; D000469:Alkaline Phosphatase / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D004700:Endocrine System Diseases / Q000139:chemically induced*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006900:Hydroxylation; D006943:Hyperglycemia / Q000139:chemically induced; D006996:Hypocalcemia / Q000139:chemically induced; D007031:Hypothalamus / Q000187:drug effects; D007700:Kinetics; D008659:Metabolic Diseases / Q000139:chemically induced*; D010281:Parathyroid Hormone / Q000378:metabolism; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000187:drug effects; D013972:Thyrotropin / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D001786:Blood Glucose; D010281:Parathyroid Hormone; D014284:Triiodothyronine; D010672:Phenytoin; D013972:Thyrotropin; D000469:Alkaline Phosphatase; D006854:Hydrocortisone